AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26912213
Drug: Dexamphetamine (DEX)
RxNorm normalized name: Dexamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamphetamine (DEX) 20 mg
Trial: 21342412
Drug: Saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 5 mg + Metformin 500 mg
Trial: 21342412
Drug: Saxagliptin 10
RxNorm normalized name: Dapagliflozin/Saxagliptin 10 MG-5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 10 mg + Metformin 500 mg
Trial: 15545304
Drug: Fenoldopam (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoldopam (selective dopamine-1 receptor agonist)
Trial: 11751780
Drug: Once-daily (od)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily (od) vancomycin
Trial: 11751780
Drug: Twice-daily (bd)
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily (bd) vancomycin
Trial: 8082348
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose bolus alteplase (n = 96)
Trial: 8082348
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose 100 mg/2 h alteplase (n = 44)
Trial: 10622071
Drug: Cefixime 200
RxNorm normalized name: cefixime 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime 200 mg b.d.
Trial: 2530542
Drug: Amoxicillin 1
RxNorm normalized name: amoxicillin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1 g b.d.
Trial: 31885300
Drug: Metronidazole combined
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole combined with debridement gel
Trial: 31885300
Drug: Wet dressing
RxNorm normalized name: wet dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wet dressing therapy combined with silver sulfadiazine
Trial: 19750263
Drug: Extra parenteral
RxNorm normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra parenteral fluid therapy
Trial: 16469617
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (25, 50, or 100 mg)
Trial: 11096147
Drug: Increased erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased erythropoietin (Epo) at Hb levels falling below 10.5 g/dl (group A)
Trial: 11096147
Drug: Increased erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased erythropoietin (Epo) at Hb levels falling below 11.5 g/dl (group B)
Trial: 11096147
Drug: Reduction in
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction in Epo dose at Hb levels above 12.0 g/dl (group C)
Trial: 9415569
Drug: Ganciclovir (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir (6 mg/kg once a day from day 1 to day 30, then 6 mg/kg once a day, Monday through Friday, until day 100)
Trial: 8558201
Drug: Busulfan (BU)
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan (BU) 7 mg/kg, Cyclophosphamide (CY) 50 mg/kg, Total-body irradiation (TBI) 12 Gy
Trial: 8558201
Drug: Conventional Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Cyclophosphamide (CY) 120 mg/kg and TBI (historical control)
Trial: 6126901
Drug: Chlorpromazine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (50 mg)
Trial: 6337363
Drug: Objective laboratory
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Objective laboratory tests indicating good prognosis (total serum protein >= 6 g%, SGOT <= 40 mU/ml, total serum bilirubin <= 0.6 mg%)
Trial: 27871576
Drug: High-dose remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose remifentanil (effect site concentration of 4 ng/mL)
Trial: 27871576
Drug: Low-dose remifentanil
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose remifentanil (effect site concentration of 1 ng/mL)
Trial: 27871576
Drug: Intravenous ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous ibuprofen (800 mg)
Trial: 20361466
Drug: Rituximab added
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab added to standard chemotherapy regimens
Trial: 20361466
Drug: Monoclonal antibody-based
RxNorm normalized name: SARS-CoV-2 antibody-based IVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody-based therapy
Trial: 15755830
Drug: Dark chocolate
RxNorm normalized name: Ensure Original Dark Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dark chocolate (100 g containing approximately 500 mg polyphenols)
Trial: 3933604
Drug: Low-dose 15
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose 15 MeV neutrons (LDN)
Trial: 3933604
Drug: High-dose 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose 15 MeV neutrons (HDN)
Trial: 3933604
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of photon and neutron therapy
Trial: 8256468
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antioxidant therapy)
Trial: 24817601
Drug: Oral imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral imatinib at doses ranging between 300 and 800 mg
Trial: 22335737
Drug: Semuloparin 20
RxNorm normalized name: Semuloparin
DrugBank: Semuloparin (DB06294)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semuloparin 20 mg once daily
Trial: 17401042
Drug: Pharmacotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy with lower anxiety
Trial: 17401042
Drug: Pharmacotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy with higher anxiety
Trial: 10840425
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy (neodymium:YAG noncontact visual prostate ablation)
Trial: 9356557
Drug: Personal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal therapy among patients living with family
Trial: 9356557
Drug: Personal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal therapy among patients living independently
Trial: 9356557
Drug: Family and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family and supportive therapies among patients living with family
Trial: 9356557
Drug: Supportive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive therapy among patients living independently
Trial: 8457085
Drug: Indobufen (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen (oral antiplatelet agent)
Trial: 26646803
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (G2) received 1 L of PEG in the day before SBCE and 1 L of PEG in the morning before SBCE (time between PEG and SBCE=4 h)
Trial: 26646803
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (G1) received 2 L of PEG in the day before SBCE (time between PEG and SBCE=10 h)
Trial: 24160904
Drug: Pulsed Nd:YAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Nd:YAG laser treatment plus standard wound care
Trial: 24160904
Drug: Placebo laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laser treatment plus standard wound care
Trial: 18654867
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg (after dosage increase)
Trial: 18654867
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg with compliance enhancement tools
Trial: 14501815
Drug: Leuprorelin acetate
RxNorm normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leuprorelin acetate (GnRH agonist) for 3 months
Trial: 10898414
Drug: Intracoronary radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary radiation (gamma and beta emitters), maximum dose to the vessel wall was 30 to 55 Gy, followed by antiplatelet therapy (aspirin and either ticlopidine or clopidogrel for one month).
Trial: 10898414
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (no radiation), followed by antiplatelet therapy (aspirin and either ticlopidine or clopidogrel for one month).
Trial: 9372677
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 150 mg/kg in 250 ml D5W
Trial: 9372677
Drug: Placebo (CON)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (CON) 250 ml D5W
Trial: 2427393
Drug: Oral urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral urokinase
Trial: 30613009
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment combined with traditional Chinese medicine retention enema (Control)
Trial: 27418333
Drug: Low-concentration contrast
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-concentration contrast agents (270 and 320 mg iodine/ml)
Trial: 27418333
Drug: High-concentration contrast
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-concentration contrast agent (370 mg iodine/ml)
Trial: 22916818
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g isolated yellow pea protein (P20)
Trial: 22916818
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g isolated yellow pea protein (P10)
Trial: 22916818
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g isolated yellow pea fibre (F10)
Trial: 22916818
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g isolated yellow pea fibre (F20)
Trial: 18678301
Drug: CP-778,875 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-778,875 2 mg/day
Trial: 18678301
Drug: CP-778,875 0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-778,875 0.5, 2, or 6 mg/day
Trial: 18678301
Drug: CP-778,875 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-778,875 6 mg/day
Trial: 12027463
Drug: Immune modulation
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune modulation therapy (IMT) - 10 ml of citrated autologous blood administered by intra-muscular injection after exposure to UV light and oxidisation, 6 injections over 3 weeks followed by 3 weeks rest, with 2-4 courses depending on response.
Trial: 12027463
Drug: Immune modulation
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune modulation therapy (IMT) - subgroup analysis for short distance claudicants
Trial: 15613167
Drug: Butorphanol nasal
RxNorm normalized name: butorphanol nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butorphanol nasal spray 1 mg followed by optional second 1 mg dose
Trial: 15613167
Drug: Fiorinal with
RxNorm normalized name: Fiorinal with Codeine
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fiorinal with Codeine (one capsule containing butalbital 50 mg, caffeine 40 mg, aspirin 325 mg, and codeine phosphate 30 mg)
Trial: 27008577
Drug: Topical ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ropivacaine (injected at three portal sites and atomized in the abdominal cavity)
Trial: 27008577
Drug: Topical ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ropivacaine
Trial: 22099039
Drug: Magnesium oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium oxide (500 mg twice a day)
Trial: 15683891
Drug: Combination neomycin‐polymyxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination neomycin‐polymyxin B‐hydrocortisone
Trial: 7328569
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of levamisole on 3 consecutive days
Trial: 7328569
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of levamisole once weekly
Trial: 20053398
Drug: 200mg of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg of oral mifepristone followed by 400 microg of oral misoprostol (group 1)
Trial: 20053398
Drug: 800 microg
RxNorm normalized name: Fentanyl 800 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 microg of sublingual misoprostol repeated every 4 hours for up to a maximum of 3 doses (group 2)
Trial: 16468528
Drug: Rofecoxib 25
RxNorm normalized name: rofecoxib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 25 mg preoperatively
Trial: 15211533
Drug: Light therapy
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light therapy (5000 lux for 50 minutes per day for 5 days)
Trial: 4034296
Drug: Subcutaneous growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous growth hormone therapy
Trial: 4034296
Drug: Intramuscular growth
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular growth hormone therapy
Trial: 29996928
Drug: Sequential engagement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential engagement strategy starting with nurses then involving doctors
Trial: 27094945
Drug: PF-06743649 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06743649 (40 mg dose)
Trial: 22891748
Drug: Azithromycin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (30 mg/kg once a week)
Trial: 18723857
Drug: Morphine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (100 microg kg(‐1) loading dose; 10-30 microg kg(‐1) h(‐1) infusion for 14 days)
Trial: 12658028
Drug: Guanabenz (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanabenz (2 mg/day)
Trial: 12658028
Drug: Guanabenz (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanabenz (4 mg/day)
Trial: 9444445
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug treatment (Control)
Trial: 29032449
Drug: Self-Help Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-Help Cognitive Behavioral Treatment (SHCBT)
Trial: 27119581
Drug: Softgel capsule
RxNorm normalized name: Renal Softgel Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Softgel capsule (diclofenac potassium 50 mg)
Trial: 27119581
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution (diclofenac potassium 50 mg)
Trial: 27119581
Drug: Tablet (diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet (diclofenac potassium 50 mg)
Trial: 27119581
Drug: Softgel capsule
RxNorm normalized name: Renal Softgel Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Softgel capsule vs Oral solution
Trial: 27119581
Drug: Softgel capsule
RxNorm normalized name: Renal Softgel Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Softgel capsule vs Tablet
Trial: 27119581
Drug: Softgel capsule
RxNorm normalized name: Renal Softgel Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Softgel capsule
Trial: 22367274
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy by a trained nurse for 10 weeks
Trial: 20139154
Drug: i.p. chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.p. chemotherapy
Trial: 15839930
Drug: ESWL (second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESWL (second treatment)
Trial: 6865429
Drug: Low alcohol
RxNorm normalized name: Low alcohol beer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low alcohol doses
Trial: 6865429
Drug: High alcohol
RxNorm normalized name: High alcohol lager
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High alcohol doses
Trial: 22865490
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg tramadol and 100 mg dexketoprofen trometamol
Trial: 22865490
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg tramadol with 100 ml 0.9% normal saline
Trial: 19937984
Drug: Spinal saddle
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal saddle block (1.0 ml 0.5 per cent hyperbaric bupivacaine)
Trial: 19937984
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia (TIVA) with propofol and fentanyl
Trial: 15800328
Drug: Parenteral hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral hydration with 1,000 mL administered over 4 hours for 2 days
Trial: 15800328
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 100 mL normal saline administered over 4 hours for 2 days
Trial: 22459230
Drug: Parenteral hydration
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral hydration
Trial: 11921156
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg per day for the first four weeks, then 10 mg per day thereafter)
Trial: 334478
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg flurbiprofen daily
Trial: 26142337
Drug: FRG +
RxNorm normalized name: Fampridine
DrugBank: Dalfampridine (DB06637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FRG + GP chemotherapy
Trial: 16571285
Drug: GP chemotherapy
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP chemotherapy alone
Trial: 15365928
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural block with 7 mL of lidocaine 2% and repeated doses of 5 mL of lidocaine 2% during the operation.
Trial: 15365928
Drug: Indomethacin suppository
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin suppository (NSAID)
Trial: 11136300
Drug: Oral verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral verapamil 80 mg
Trial: 1333267
Drug: Intravenous 6-thioguanine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 6-thioguanine (6-TG) at 55 mg/m2 administered over 30 minutes for 5 consecutive days, repeated every 35 days.
Trial: 1333267
Drug: Cisplatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (100 mg/m2 on day 1), 5-fluorouracil (800 mg/m2/day as continuous intravenous infusion over 5 days), and oral leucovorin (100 mg every 4 hours during the entire duration of cisplatin and 5-FU infusions), repeated every three weeks.
Trial: 30420289
Drug: LCB01-0371 400-1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCB01-0371 400-1600 mg BID for 7 days
Trial: 30420289
Drug: LCB01-0371 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCB01-0371 800 mg single oral dose
Trial: 30420289
Drug: LCB01-0371 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCB01-0371 400 mg tablet
Trial: 23040973
Drug: Long-term growth
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term growth hormone (GH) therapy
Trial: 17954694
Drug: Intravenous tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tigecycline (100 mg loading dose followed by 50 mg every 12 h or 50 mg loading dose followed by 25 mg every 12 h)
Trial: 6365803
Drug: Penbutolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol (40 mg daily)
Trial: 31898647
Drug: PEG‐LD 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐LD 25 mg/m2 and docetaxel 50 mg/m2
Trial: 31898647
Drug: PEG‐LD 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐LD 30 mg/m2 and docetaxel 50 mg/m2
Trial: 31898647
Drug: PEG‐LD 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐LD 30 mg/m2 and docetaxel 60 mg/m2